Micheal Naseem El Abd*, Mamdouh M Almezaien, Sherif A Reffat, Hatem H Mohamed and Meera Refaat

Department of Surgery, Vascular Surgery Unit, Suez Canal University Hospital, Ismailia, Egypt

*Corresponding Author: Micheal Naseem El Abd, Department of Surgery, Vascular Surgery Unit, Suez Canal University Hospital, Ismailia, Egypt.

Received: October 01, 2025; Published: November 30, 2025

Abstract

This study aims to assess thrombotic risk, laboratory markers, and clinical outcomes in patients with and without COVID-19 presenting with peripheral thromboembolic events (TEs), focusing on COVID-19-associated coagulopathy (CAC). A prospective observational comparative study was conducted at Suez Canal University Hospital, Ismailia, Egypt, between January and June 2023. The patients were divided into three groups: those with recent PCR-confirmed COVID-19 and TEs, those with COVID-19 but no TEs, and those with TEs without COVID-19. Demographics, symptoms, comorbidities, laboratory parameters, imaging data, and clinical outcomes were collected. Patients in the COVID-19 with TEs group demonstrated significantly higher rates of diabetes mellitus (60%), obesity (69.3%), and ICU admission (42.7%) compared to other groups (p < 0.05). D-dimer levels >9.4 μg/mL showed excellent predictive performance for TEs (AUC = 0.999, sensitivity = 100%, specificity = 97.33%, p < 0.001), whereas fibrinogen levels demonstrated moderate predictive capacity. Among therapeutic interventions, 53.3% of COVID-19 patients with TEs and 56% of non-COVID-19 patients with TEs received anticoagulation; however, 24% of COVID-19-associated TE patients ultimately required limb amputation. Despite comparable treatment protocols, clinical outcomes were notably worse among COVID-19 patients with TEs. The study highlights the severity of peripheral thromboembolic complications in COVID-19 patients, highlighting the importance of aggressive risk stratification and intensified anticoagulation strategies. It suggests further multicentric studies to refine anticoagulation protocols and investigate long-term vascular outcomes post-COVID-19, highlighting the need for further research.

 Keywords: COVID-19; Thromboembolic Events; Coagulopathy; D-Dimer; Anticoagulation

References

1. Lu R., et al. “Genomic Characterisation and Epidemiology of 2019 Novel Coronavirus: Implications for Virus Origins and Receptor Binding”. The Lancet 395.10224 (2021): 565-574.
2. Schnittler HJ and Feldmann H. “Viral Hemorrhagic Fever–a Vascular Disease?” Thrombosis and Haemostasis6 (2003): 967-972.
3. Iba T., et al. “Managing Thrombosis and Cardiovascular Complications of COVID-19: Answering the Questions in COVID-19-Associated Coagulopathy”. Expert Review of Respiratory Medicine 8 (2021): 1003-1011.
4. Biswas S., et al. “Blood Clots in COVID-19 Patients: Simplifying the Curious Mystery”. Medical Hypotheses 146 (2021): 110371.
5. Klok FA., et al. “Incidence of Thrombotic Complications in Critically Ill ICU Patients with COVID-19”. Thrombosis Research 191 (2020): 145-147.
6. Yu Y., et al. “Incidence and Risk Factors of Deep Vein Thrombosis in Hospitalized COVID-19 Patients”. Clinical and Applied Thrombosis/Hemostasis 26 (2020): 1076029620953217.
7. Bunce PE., et al. “Pandemic H1N1 Influenza Infection and Vascular Thrombosis”. Clinical Infectious Diseases2 (2011): e14-e7.
8. Naqvi IH., et al. “COVID-19-associated coagulopathy and thromboembolism: determination of their patterns and risk factors as predictors of mortality among severe COVID-19 patients”. Current Vascular Pharmacology 1 (2022): 77-86.
9. Plášek J., et al. “COVID-19 associated coagulopathy: Mechanisms and host-directed treatment”. The American Journal of the Medical Sciences6 (2022): 465-475.
10. Tang D., et al. “The hallmarks of COVID-19 disease”. PLoS Pathogens5 (2020): e1008536.
11. Mei ZW., et al. “Role of von Willebrand factor in COVID-19 associated coagulopathy”. The Journal of Applied Laboratory Medicine5 (2021): 1305-1315.

Citation

Citation: Micheal Naseem El Abd., et al. “Assessment of Peripheral Thromboembolic Events Risk Factors Among Covid-19 Patients in Suez Canal University Hospital”.Acta Scientific Medical Sciences 9.12 (2025): 57-63.

Copyright

Copyright: © 2025 Micheal Naseem El Abd., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.